F2 Genotype

Inherited clotting risk usually stays invisible until something sets it off: a long flight, a knee replacement, a pregnancy, a new birth control pill. The common variant in this gene raises the odds of a first venous clot about two- to fivefold, and it turns up in roughly 1 in 20 people who have already had one.

Sequencing reads clinically important parts of the gene instead of checking a single spot, which is the practical difference between this test and the older one most labs run. The common variant matters most, but rare variants are the reason sequencing can sometimes add information for people with unexplained clots and a clean standard workup.

What the Test Actually Reads

F2, also called coagulation factor II, is the gene for prothrombin. It sits on chromosome 11 and runs about 21,000 letters long across 14 coding segments. Its product is the raw material your body converts into thrombin. Thrombin turns liquid blood into a solid clot.

A sequencing report looks for inherited spelling changes in those instructions. It does not measure how much prothrombin is circulating or how fast you clot. The changes fall into three groups.

• The common variant: known as G20210A, it sits near the tail end of the gene, where the instructions are processed before protein is made. It doesn't change the protein itself. It makes your liver produce more prothrombin, and more prothrombin gives your blood more capacity to generate thrombin.
• Rare gain-of-function variants: changes at a position called Arg596 produce a version of thrombin that resists antithrombin. Antithrombin is your body's main brake on clotting. Carriers can generate too much thrombin even when routine clotting tests look ordinary.
• Rare loss-of-function variants: a scattered set of changes reduce prothrombin production or cripple the protein, producing a bleeding tendency rather than a clotting one.

That second group creates a trap worth knowing about. In a study of Chinese patients with venous clots, carriers of the Arg596Gln change had moderately reduced clotting activity on a standard assay, which reads like a bleeding risk, alongside strong antithrombin resistance and elevated thrombin generation, which is the opposite. Low measured activity here does not automatically mean low clotting risk.

Venous Clots

This is the association the gene is known for, and it is solid. Compared with non-carriers, someone with a single copy of the common variant has about two to five times the risk of a first deep vein clot or lung clot. Two copies, or one copy alongside a Factor V Leiden variant, pushes it higher still.

Sources: Manderstedt et al. (population cohort); Simone et al. (pooled analysis); Folsom et al. (prospective cohort).

What this means for you: a few times a small number is still a small number in an ordinary year. Baseline venous clot risk in the general population runs around one in a thousand per year, so a carrier's everyday risk stays low. The genotype earns its keep at the moments when risk multiplies anyway, which is surgery, immobility, pregnancy, and estrogen.

Why It Predicts a First Clot Better Than a Second

Here is where the evidence gets counterintuitive. A systematic review of prospective studies found that people carrying one copy of Factor V Leiden had a modestly raised risk of a second clot, while carriers of this variant showed no clear increase. In 354 older adults followed after a first unprovoked clot, neither variant predicted recurrence at all. A large systematic review in JAMA found no direct evidence that testing improves outcomes in adults who have already had a clot, or in their relatives.

That is not a contradiction, and it does not mean the genotype is meaningless. Once you have had a clot, the clot itself becomes the dominant predictor of the next one, and the decision about how long to stay on blood thinners turns on whether the event was provoked by something temporary. Genotype adds little on top of that. The information is most useful before anything has happened, especially in relatives making estrogen, pregnancy, or surgery decisions.

Clots in Unusual Places

Not every clot happens in a leg. The portal vein carries blood from the intestines to the liver. A pooled analysis found the common variant associated with portal vein clots in people without cirrhosis. Budd-Chiari syndrome is a different blockage in the liver's draining veins. The same analysis did not find a clear link to that condition.

Clots in the veins draining the brain are also more common in carriers, and a meta-analysis found the strength of that link varies considerably by country of origin. If you have had a clot somewhere unusual, this is one of the genetic findings that can change the workup.

Arteries, Stroke, and Age

In a large prospective study of US men, this variant showed no association with heart attack or stroke. That result has held up as the general answer for middle-aged and older adults.

Young people are different. Two meta-analyses covering 3,586 cases and 6,440 controls found the variant linked to arterial ischemic stroke in children and young adults. A case-control study of 270 young people put the risk of cerebral ischemia in carriers at roughly four times that of non-carriers.

The reconciliation is age and mechanism. Arterial events after 55 are mostly driven by decades of plaque buildup, and a modest clotting tendency gets swamped by that. In a 30-year-old with clean arteries and no traditional risk factors, a clotting tendency has room to be the whole story. Human genetic analyses point the same direction: people whose genes predict lower factor II blood levels have lower rates of stroke caused by a traveling clot.

Pregnancy and Recurrent Loss

Mechanistic work shows variants in the gene's tail end can raise prothrombin output. Case reports and older association studies linked these variants to fetal loss, growth restriction, pre-eclampsia, and placental problems. Larger prospective studies have not backed that up as a reason to test.

In 1,186 women investigated for reproductive failure, carrier frequency matched the general population. A study of 5,345 unselected Italian women concluded that screening low-risk women is not warranted. An evidence review found that giving blood thinners to carriers with recurrent pregnancy loss did not improve live birth rates and carried treatment harms.

So if you carry the variant and have had losses, that combination is not by itself a reason to start anticoagulation in a future pregnancy. It is a reason to talk with an obstetrician about clot prevention around delivery, which is a separate question with better evidence behind it.

Cancer, and Carrying Two Variants at Once

A systematic review found this variant to be a risk factor for venous clots in people with cancer, alongside Factor V Leiden and non-O blood type. Cancer already multiplies clot risk substantially, and this stacks on top.

Stacking is also the main reason to pair this test with Factor V Leiden. Carrying one copy of each is roughly as common as carrying two copies of Factor V Leiden, and analyses spanning the FinnGen and UK Biobank cohorts and then more than 876,000 people found that combination carries higher clot risk than either alone. If you only run one companion test, run that one.

What Sequencing Finds That a Spot-Check Misses

Older standard testing looks at one position and reports whether the common variant is there. Sequencing reads the protein-coding regions and the junctions between them, which is how rare variants get found, including variants around Arg596 that cause antithrombin resistance and other rare coding changes reported in thrombosis families.

The yield depends heavily on who is tested. In 133 people with unexplained clots and a completely negative standard thrombophilia workup, a sequencing panel produced findings of uncertain meaning in about a third. In a different, bleeding-focused cohort of 515 patients with documented inherited clotting factor deficiencies, a 22-gene panel gave an answer in roughly two thirds, and 37% of the 460 variants it found had never been reported before.

One limitation: across large clinical testing datasets, not this gene specifically, about one in seven disease-causing variants is technically difficult for sequencing to call. Changes buried deep inside the non-coding stretches of a gene, and large rearrangements, are the known blind spots. A clean result narrows the possibilities considerably. It does not eliminate them.

A One-Time Result

Your DNA sequence does not change, so this is a test you run once and keep for life. There is no trend to track and no reason to repeat it, with one exception: if the call came from a consumer chip-based report rather than clinical sequencing, confirm it with a clinical-grade method before you act on it. Different technologies have different error profiles, and a single-position call from a genotyping array is not the same evidence as clinical sequencing.

What does need ongoing attention is everything downstream. If you carry a risk variant, the tests worth repeating are the situational ones: a clotting workup before major surgery, and a conversation about prevention ahead of pregnancy, prolonged immobility, or starting estrogen. The value of this result builds over years of decisions, not over repeat tests.

What to Do With a Positive Result

Start by finding out what else you carry. Order Factor V Leiden if you have not already, since that is where the risk stacks. If sequencing turned up a rare change in the protein-coding part of the gene rather than the common tail-end variant, add a factor II activity assay, because activity helps separate a quantitative shortage from a dysfunctional protein that looks low on paper but drives clotting.

Then fill in the rest of the inherited picture: antithrombin activity, protein C, and protein S. Lupus anticoagulant, cardiolipin antibodies, and beta-2 glycoprotein I antibodies cover the acquired side, which matters because acquired causes are more common than inherited ones and are handled very differently. One caution on timing: some blood thinners, especially direct oral anticoagulants, interfere with several of these functional assays, so if you are already on a blood thinner, the results need interpreting with that in mind.

The combinations that warrant a hematologist are specific: a rare coding variant, two risk variants together, a personal history of clots at a young age or in an unusual location, or several affected relatives. A single copy of the common variant with no personal or family clot history is a risk flag you manage situationally, not a diagnosis and not a reason to start lifelong anticoagulation. A genetic counselor is worth involving when you are deciding whom in the family to test and what to tell them.

One practical point: among 2,260 people on extended anticoagulation after a venous clot, carriers of Factor V Leiden or this variant had a lower rate of major and clinically relevant bleeding than non-carriers. Carrying a clotting variant does not appear to make blood thinners more dangerous for you.

When Results Can Be Misleading

The confounders here are different from those affecting a blood level. Nothing you eat, do, or take changes your sequence. What changes is how much a given result tells you.

• Panel coverage: the assay reports what it was designed to detect. Changes buried deep in the non-coding stretches of the gene and large structural rearrangements are known blind spots, so a negative result narrows the field without closing it.
• Ancestry: the common variant is largely a European-origin allele. It was entirely absent from a Chinese cohort of 367 people with chronic clot-related pulmonary hypertension, while rarer population-specific changes like Arg596Gln carried the risk instead. A negative result means something different depending on where your family comes from.
• Variants of uncertain significance: in the 133-person panel study, roughly a third of findings fell into the uncertain category. These are observations awaiting functional evidence, not diagnoses, and treating them as diagnoses is the most common error with sequencing results.
• Consumer reports versus clinical sequencing: a single-position call from a direct-to-consumer array is not equivalent to clinical-grade sequencing of the gene. Confirm before you change anything.
• Germline versus tumor-only sequencing: a clotting result from tumor tissue is not the same as an inherited call. Confirm suspected inherited findings with a clinical germline sample.

There is also one thing this test deliberately cannot be replaced by. Carriers of the common variant generate more thrombin than non-carriers, and that excess is not fully explained by how much prothrombin is circulating in their blood. Measuring the protein level is not a substitute for reading the gene.